Imbrium Therapeutics

What Imbrium Therapeutics does

Imbrium Therapeutics L.P. was a clinical-stage biopharmaceutical company headquartered at 201 Tresser Boulevard in Stamford, Connecticut, that operated as a wholly-owned subsidiary of Purdue Pharma L.P. Founded in 2018 and employing between 11 and 50 staff, the company focused on developing novel therapeutic candidates for serious medical conditions in three therapeutic areas: central nervous system (CNS) disorders, oncology chemotherapeutics, and non-opioid pain.

The company's pipeline consisted of investigational drug candidates rather than approved commercial products. Its lead oncology asset, Tinostamustine, is a first-in-class small molecule that combines DNA alkylating activity with histone deacetylase (HDAC) inhibition, representing a dual-mechanism architecture. Tinostamustine was being evaluated in the GBM AGILE international adaptive platform trial for glioblastoma (GBM), activated in partnership with the Global Coalition for Adaptive Research (GCAR). The trial operates at approximately 60 sites across six countries and had screened over 2,600 patients since its 2019 launch. The second notable asset, Sunobinop, was advanced for non-opioid pain and other CNS indications. Imbrium held no publicly disclosed patents or certifications in the provided data.

As a clinical-stage entity, Imbrium did not generate commercial product revenue; its intended monetization path was licensing and royalty agreements with larger pharmaceutical partners following regulatory approval. The company relied on its parent Purdue Pharma L.P. for funding and infrastructure. On May 1, 2026, Imbrium Therapeutics and Purdue Pharma permanently ceased operations, with asset development oversight transferred to a newly formed entity called Knoa Pharma. The company's go-to-market motion was oriented around scientific publication, industry conference participation, and partnering with commercial and academic collaborators rather than direct product commercialization.

Name

Imbrium Therapeutics

Legal name

Imbrium Therapeutics L.P.

Website

https://imbriumthera.com

Company type

Private

Founded year

2018

Operating status

Closed

Headcount range

11–50 employees

Short description

Imbrium Therapeutics was a clinical-stage biopharmaceutical subsidiary of Purdue Pharma L.P., developing investigational drug candidates including Tinostamustine (for glioblastoma) and Sunobinop for CNS and non-opioid pain indications until its permanent cessation of operations on May 1, 2026.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Clinical-stage biopharmaceuticals
• Investigational oncology therapeutics
• CNS disorder treatments
• Non-opioid pain therapeutics
• Novel drug pipeline development

Headquarters

HQ city

Stamford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, Imbrium's revenue model is based on developing and commercializing novel therapeutics. The company was focused on advancing pipeline candidates through clinical development with the goal of obtaining regulatory approvals and commercializing products, likely through licensing agreements or direct commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Imbrium Therapeutics was a clinical-stage biopharmaceutical company dedicated to developing novel therapy candidates for serious medical conditions, with therapeutic areas spanning CNS disorders, oncology chemotherapeutics, and non-opioid pain. The company advanced a pipeline of investigational drug candidates, including Sunobinop for CNS indications and Tinostamustine, a first-in-class agent for glioblastoma, through clinical development in collaboration with academic and commercial partners. Imbrium operated as a subsidiary of Purdue Pharma L.P. and permanently ceased operations on May 1, 2026.

Product overview

Imbrium Therapeutics is a clinical-stage biopharmaceutical company that ceased operations on May 1, 2026. The company developed a pipeline of novel therapy candidates focused on serious medical conditions, with key investigational drugs including Sunobinop (a CNS candidate) and Tinostamustine (a first-in-class oncology agent combining DNA alkylating activity with HDAC inhibition for glioblastoma). Their therapeutic areas included CNS disorders, oncology chemotherapeutics, and non-opioid pain. Knoa Pharma now oversees development of these assets following the closure. The product portfolio consisted of multiple investigational candidates in various stages of clinical development rather than approved commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Sunobinop

Quantifiable outcome

• Tinostamustine being evaluated in GBM AGILE trial - an international adaptive platform trial designed to generate data supporting regulatory submissions to the FDA and other health authorities

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Global Coalition for Adaptive Research (GCAR)coreStrategic or Co-development Partner · 8 April 2026GCAR and Imbrium's parent company Purdue Pharma L.P. announced the activation of investigational tinostamustine in GBM AGILE, an international adaptive platform trial for glioblastoma. Tinostamustine, a first-in-class agent combining DNA alkylating activity with HDAC inhibition, is being evaluated in newly diagnosed GBM patients and a recurrent GBM cohort. GBM AGILE has screened over 2,600 patients at approximately 60 sites across six countries since its 2019 launch and is designed to generate data supporting regulatory submissions.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Kazia Therapeutics: Kazia Therapeutics is a clinical-stage oncology company focused on glioblastoma (e.g., paxalisib), directly comparable to Imbrium's tinostamustine GBM program in indication, development stage, and target patient population.
• BioXcel Therapeutics: BioXcel Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics in neuroscience (agitation in dementia, ADHD) and immuno-oncology — directly comparable to Imbrium's CNS and oncology pipeline focus.
• Tonix Pharmaceuticals: Tonix Pharmaceuticals is a clinical-stage company with pipeline assets spanning CNS disorders and non-opioid pain, directly overlapping Imbrium's CNS and non-opioid pain therapeutic areas.
• Knoa Pharma: Knoa Pharma is the successor entity that has assumed oversight of Imbrium Therapeutics' pipeline assets (including tinostamustine and sunobinop) following Imbrium's May 1, 2026 cessation of operations. It is directly comparable as it is advancing the same clinical-stage CNS and oncology candidates.

Emerging players

• Aprea Therapeutics: Aprea Therapeutics is a clinical-stage oncology company developing small-molecule therapies targeting DNA damage response pathways, comparable to Imbrium's DNA-targeting mechanism in tinostamustine.
• Kura Oncology: Kura Oncology is a clinical-stage precision oncology company developing small-molecule candidates, comparable to Imbrium's clinical-stage tinostamustine oncology development model and stage.

Broad incumbents

• Denali Therapeutics: Denali Therapeutics is a larger clinical-stage biotechnology company focused on neurodegeneration and CNS disorders, broadly comparable to Imbrium's CNS pipeline focus with significantly greater scale and capital base.
• Indivior: Indivior is a specialty pharmaceutical company focused on addiction and substance use disorders including alcohol use disorder, overlapping with Imbrium's sunobinop AUD program at a more advanced commercialization stage.
• Alkermes: Alkermes is an established biopharmaceutical company with franchises in CNS and addiction medicine (e.g., VIVITROL for alcohol use disorder), directly overlapping Imbrium's sunobinop AUD indication while operating at substantially greater scale.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a global biopharmaceutical company with major oncology and neuroscience franchises, comparable as a potential large-licensing partner or acquirer of clinical-stage CNS/oncology assets like Imbrium's pipeline.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ImbriumThera

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imbrium Therapeutics